
EquitySector - HealthcareVery High Risk
NAV (30-Apr-26)
Returns (Since Inception)
Fund Size
₹8 Cr
Expense Ratio
0.11%
ISIN
INF769K01QA6
Minimum SIP
-
Exit Load
-
Inception Date
11 Feb 2026
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+2.93%
— (Cat Avg.)
| Equity | ₹7.62 Cr | 99.94% |
| Others | ₹0 Cr | 0.06% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹0.76 Cr | 10.03% |
| Dr Reddy's Laboratories Ltd | Equity | ₹0.51 Cr | 6.75% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹0.51 Cr | 6.74% |
| Divi's Laboratories Ltd | Equity | ₹0.51 Cr | 6.67% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹0.48 Cr | 6.32% |
| Cipla Ltd | Equity | ₹0.46 Cr | 6.08% |
| Lupin Ltd | Equity | ₹0.38 Cr | 4.95% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.3 Cr | 3.90% |
| Fortis Healthcare Ltd | Equity | ₹0.28 Cr | 3.66% |
| Laurus Labs Ltd | Equity | ₹0.26 Cr | 3.41% |
| Aurobindo Pharma Ltd | Equity | ₹0.25 Cr | 3.22% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.22 Cr | 2.83% |
| Alkem Laboratories Ltd | Equity | ₹0.21 Cr | 2.73% |
| Biocon Ltd | Equity | ₹0.17 Cr | 2.27% |
| Mankind Pharma Ltd | Equity | ₹0.15 Cr | 2.00% |
| Ipca Laboratories Ltd | Equity | ₹0.15 Cr | 1.96% |
| Zydus Lifesciences Ltd | Equity | ₹0.15 Cr | 1.92% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.11 Cr | 1.50% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.11 Cr | 1.49% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.1 Cr | 1.36% |
| Abbott India Ltd | Equity | ₹0.09 Cr | 1.19% |
| Gland Pharma Ltd | Equity | ₹0.09 Cr | 1.19% |
| Sai Life Sciences Ltd | Equity | ₹0.09 Cr | 1.18% |
| Acutaas Chemicals Ltd | Equity | ₹0.09 Cr | 1.17% |
| Ajanta Pharma Ltd | Equity | ₹0.08 Cr | 1.05% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.07 Cr | 0.98% |
| Neuland Laboratories Ltd | Equity | ₹0.07 Cr | 0.92% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.07 Cr | 0.90% |
| Wockhardt Ltd | Equity | ₹0.07 Cr | 0.86% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.06 Cr | 0.83% |
| Granules India Ltd | Equity | ₹0.06 Cr | 0.80% |
| Natco Pharma Ltd | Equity | ₹0.06 Cr | 0.77% |
| Piramal Pharma Ltd | Equity | ₹0.06 Cr | 0.75% |
| Global Health Ltd | Equity | ₹0.05 Cr | 0.72% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.05 Cr | 0.72% |
| Syngene International Ltd | Equity | ₹0.05 Cr | 0.65% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.05 Cr | 0.63% |
| Pfizer Ltd | Equity | ₹0.05 Cr | 0.63% |
| Jubilant Pharmova Ltd | Equity | ₹0.04 Cr | 0.58% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.04 Cr | 0.51% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.04 Cr | 0.48% |
| Cohance Lifesciences Ltd | Equity | ₹0.03 Cr | 0.43% |
| Poly Medicure Ltd | Equity | ₹0.03 Cr | 0.40% |
| Indegene Ltd | Equity | ₹0.03 Cr | 0.40% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.03 Cr | 0.37% |
| Anthem Biosciences Ltd | Equity | ₹0.03 Cr | 0.36% |
| Concord Biotech Ltd | Equity | ₹0.02 Cr | 0.30% |
| Caplin Point Laboratories Ltd | Equity | ₹0.02 Cr | 0.26% |
| Treps | Cash - Repurchase Agreement | ₹0.01 Cr | 0.17% |
| Net Receivables / (Payables) | Cash | ₹-0.01 Cr | 0.12% |
| Blue Jet Healthcare Ltd | Equity | ₹0.01 Cr | 0.10% |
Large Cap Stocks
46.50%
Mid Cap Stocks
33.06%
Small Cap Stocks
20.39%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹7.53 Cr | 98.77% |
| Basic Materials | ₹0.09 Cr | 1.17% |
Standard Deviation
This fund
--
Cat. avg.
16.46%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.96
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.70
Higher the better

Since February 2026
Since February 2026
ISIN INF769K01QA6 | Expense Ratio 0.11% | Exit Load - | Fund Size ₹8 Cr | Age 2 months | Lumpsum Minimum - | Fund Status Open Ended Investment Company | Benchmark Nifty 500 Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,06,170 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments